Diabetes markets

On the surface, Johnson & Johnson's decision to drop Amylin Pharmaceuticals Inc.'s pramlintide in favor of Ergo Science Corp.'s Ergoset to treat diabetes might seem a relatively straightforward decision.

Although J&J is willing to say almost nothing about its diabetes program or strategy, Ergoset appears to fulfill the pharma company's desire for a broad-brush product...